Clinical for proposed intervention Following a 2006 MSAC assessment, breast MRI was conditionally recommended for use as an additional test in the diagnosis of breast cancer in asymptomatic women with a high risk of developing breast cancer when used as part of organised surveillance. Since February 2009, breast MRI has been available on the MBS as an interim funded item. The 2006 assessment also assessed breast MRI as a replacement to CBE, mammography ± ultrasound, however this was not recommended by MSAC at the time and is not being considered here. What is being assessed is: use of breast MRI for the screening of high risk women in addition to an organised surveillance program, as recommended by MSAC in 2007 (MSAC 2006). As such no change is being proposed to the use of breast MRI in the clinical pathway from what was recommended in this review;and the inclusion of additional high risk patient populations in MBS item 63464. The change in the proposed patient population will see additional patients screened who would not previously have had access to this item. This inclusion of the additional high risk patient populations are consistent with those risk factors that have been identified by the NBOCC 2009 associated with a strong Relative Risk (RR >4) increased risk of breast cancer.
Clinical for proposed intervention Following a 2006 MSAC assessment, breast MRI was conditionally recommended for use as an additional test in the diagnosis of breast cancer in asymptomatic women with a high risk of developing breast cancer when used as part of organised surveillance. Since February 2009, breast MRI has been available on the MBS as an interim funded item. The 2006 assessment also assessed breast MRI as a replacement to CBE, mammography ± ultrasound, however this was not recommended by MSAC at the time and is not being considered here. What is being assessed is: use of breast MRI for the screening of high risk women in addition to an organised surveillance program, as recommended by MSAC in 2007 (MSAC 2006). As such no change is being proposed to the use of breast MRI in the clinical pathway from what was recommended in this review;and the inclusion of additional high risk patient populations in MBS item 63464. The change in the proposed patient population will see additional patients screened who would not previously have had access to this item. This inclusion of the additional high risk patient populations are consistent with those risk factors that have been identified by the NBOCC 2009 associated with a strong Relative Risk (RR >4) increased risk of breast cancer.
1098.1-FINAL-DAP.docx